Methanocarba cycloalkyl nucleoside analogues
CA 2397366 C · Owner: Marquez, Victor E. · Inventors: Marquez, Victor E.; Jacobson, Kenneth A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides novel nucleoside and nucleotide derivatives that are useful agonists or antagonists of P1 or P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is bonded to the constrained cycloakyl group. The compounds of the present invention are useful in the treatment or prevention of various diseases including airway diseases (through A2B A3, P2Y2 receptors), cancer (through A3 P2 receptors), cardiac arrhythmias , (through A1 receptors) cardiac ischemia (through A1, A3 , receptors) epilepsy (through A1, P2X receptors), and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 12, 2001 and granted March 15, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 12, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 12, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.